Compare · CERE vs QS
CERE vs QS
Side-by-side comparison of Cerevel Therapeutics Holdings Inc. (CERE) and QuantumScape Corporation (QS): market cap, price performance, sector, and recent activity on the wire.
Summary
- CERE operates in Health Care, while QS operates in Miscellaneous - the two are in different parts of the market.
- QS is the larger of the two at $6.09B, about 1.7x CERE ($3.50B).
- QS has hit the wire 9 times in the past 4 weeks while CERE has been quiet.
- QS has more recent analyst coverage (22 ratings vs 19 for CERE).
- Company
- Cerevel Therapeutics Holdings Inc.
- QuantumScape Corporation
- Price
- $44.97+0.81%
- $5.83+1.84%
- Market cap
- $3.50B
- $6.09B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 9
- Recent ratings
- 19
- 22
Cerevel Therapeutics Holdings Inc.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
QuantumScape Corporation
QuantumScape Corporation, a development stage company, engages in the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. The company was founded in 2010 and is headquartered in San Jose, California.
Latest CERE
- Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
- SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)
- Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.
- Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)
- Director Gordon Christopher R returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest QS
- CHIEF TECHNOLOGY OFFICER Holme Timothy converted options into 12,723 shares and sold $76,516 worth of shares (12,723 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF TECHNOLOGY OFFICER Holme Timothy covered exercise/tax liability with 34,086 shares, sold $241,109 worth of shares (41,876 units at $5.76) as part of a pre-agreed trading plan and converted options into 21,531 shares, decreasing direct ownership by 3% to 1,658,075 units (SEC Form 4) (tax withholding)
- CHIEF LEGAL OFFICER Mccarthy Michael O Iii covered exercise/tax liability with 25,709 shares, decreasing direct ownership by 2% to 1,527,774 units (SEC Form 4) (withholding obligation)
- CHIEF DEVELOPMENT OFFICER Singh Mohit covered exercise/tax liability with 34,304 shares, decreasing direct ownership by 2% to 1,737,150 units (SEC Form 4) to cover taxes
- CHIEF FINANCIAL OFFICER Hettrich Kevin covered exercise/tax liability with 31,095 shares, decreasing direct ownership by 2% to 1,785,162 units (SEC Form 4) (tax liability)
- CHIEF EXECUTIVE OFFICER Sivaram Srinivasan covered exercise/tax liability with 81,752 shares, decreasing direct ownership by 2% to 5,078,264 units (SEC Form 4) to satisfy withholding tax
- Chief Operating Officer Fasoli Luca Giovanni covered exercise/tax liability with 32,255 shares, decreasing direct ownership by 2% to 1,907,088 units (SEC Form 4) to satisfy tax liability
- SEC Form 144 filed by QuantumScape Corporation
- SEC Form 144 filed by QuantumScape Corporation
- SEC Form 10-Q filed by QuantumScape Corporation